Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Horizon Therapeutics Usa Inc. has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to 2 examiners and 2 art units, creating separate examination channels.
KOSAR, AARON J is the busiest examiner, with 1 pending matter. Counsel should tailor each response to its examination record while maintaining consistent pharmaceutical terminology where relevant.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KOSAR, AARON J | 1 | 71.3% | +29.7% |
| BORI, IBRAHIM D | 1 | 43.9% | +39.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18376677 | REDUCING IMMUNOGENICITY TO PEGLOTICASE | BORI, IBRAHIM D | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18891899 | TOLERIZATION REDUCES INTOLERANCE TO PEGLOTICASE AND PROLONGS THE URATE LOWERING EFFECT (TRIPLE) | KOSAR, AARON J | — |
| 18376677 | REDUCING IMMUNOGENICITY TO PEGLOTICASE | BORI, IBRAHIM D | — |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18891899 | TOLERIZATION REDUCES INTOLERANCE TO PEGLOTICASE AND PROLONGS THE URATE LOWERING EFFECT (TRIPLE) | KOSAR, AARON J | 1655 | DP | Non-Final OA | — | Pending | Sep 20, 2024 |
| 18376677 | REDUCING IMMUNOGENICITY TO PEGLOTICASE | BORI, IBRAHIM D | 1629 | §102§103§112 | Final Rejection | — | Pending | Oct 04, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHorizon Therapeutics Usa Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Aaron J Kosar has the most, with 1 of Horizon Therapeutics Usa Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
